Short- and intermediate-term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials .
O O O O O O O O O O O O O O O O O O O O O O B-ChemicalEntity O O O O O O O O O B-DiseaseOrPhenotypicFeature O O O O B-ChemicalEntity O O O B-DiseaseOrPhenotypicFeature O B-DiseaseOrPhenotypicFeature I-DiseaseOrPhenotypicFeature B-OrganismTaxon O O O O O